Detalhe da pesquisa
1.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood;
135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32206772
2.
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Haematologica;
106(11): 2834-2844, 2021 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33121235
3.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol;
21(9): 1188-1200, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32888452
4.
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
Blood;
135(11): 866-870, 2020 03 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31990291
5.
Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study.
J Geriatr Oncol;
14(8): 101602, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37696241